Inhalte im Video:
Produziert von:
9. Sep. 2019Prim. Dr. Markus Rauter

WCLC 2019: Die wichtigsten Abstracts zu Früherkennung und Immuntherapie

Prim. Dr. Markus Rauter, Abteilung für Lungenkrankheiten, Klinikum Klagenfurt, berichtet über Konsolidierungen beim Lungenkrebs-Screening, und neue Präparate sowie Biomarker-Erkenntnisse in der Immuntherapie auf der World Conference on Lung Cancer.

* 13 Monate und HR 0,7 beziehen sich auf das Gesamtüberleben (nicht PFS, wie im Video angegeben).

Abstracts, die im Video diskutiert werden:

PL02.02 – Lung Cancer Screenee Selection by USPSTF Versus PLCOm2012 Criteria – Interim ILST Findings
Stephen Lam

PL02.03 – Early Detection of Cancer of the Lung Scotland (ECLS): Trial Results
Frank Sullivan

PL02.04 – Blood MicroRNA and LDCT Reduce Unnecessary LDCT Repeats in Lung Cancer Screening: Results of Prospective BioMILD Trial
Ugo Pastorino

PL02.06 – In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer
Eric Lim

PL02.08 – Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
Alexander Drilon

PL02.11 – Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
Luis Paz-Ares

PR02.05 – CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
Fabrice Barlesi

PR02.02 – Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
Naiyer Rizvi

PR02.05 – KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
Corey Langer

OA04.06 – Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
Marina Garassino

EP1.01-02 – Novel Partial Tumor Irradiation Improves Treatment Outcomes for Inoperable Bulky Lung Cancer Compared with Standard of Care
Slavisa Tubin

Quelle

2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Barcelona, 7.-10.9.19